Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22237885 | 0.83 | SRC (0.36) | CYP2A6CYP1A2TSHRACHECD44 | |
| SCHEMBL18938794 | 0.83 | CYP1A2 (0.35) | CYP2A6CYP1A2TSHRACHECD44 | |
| SCHEMBL1768471 | 0.83 | MYC (0.42) | CYP2A6CYP1A2TSHRACHECD44 | |
| SCHEMBL20072679 | 0.81 | C1R (0.34) | CYP2A6CYP1A2TSHRACHECD44 | |
| SCHEMBL22357733 | 0.81 | CD44 (0.33) | CYP2A6CYP1A2TSHRACHECD44 | |
| SCHEMBL17448425 | 0.81 | TRPA1 (0.48) | CYP1A2TSHRCD44ALDH1A1CA1 | |
| SCHEMBL24625660 | 0.79 | MYC (0.48) | CYP2A6CYP1A2TSHRACHECD44 | |
| SCHEMBL21730835 | 0.79 | TDP2 (0.46) | CYP2A6CYP1A2TSHRACHECD44 | |
| SCHEMBL10212401 | 0.78 | — | — | |
| SCHEMBL18938792 | 0.78 | PARP1 (0.33) | CYP2A6CYP1A2CD44ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2251342-A1 | FUSED RING COMPOUND, METHOD FOR PRODUCING THE SAME, POLYMER, ORGANIC THIN FILM CONTAINING THE COMPOUND AND/OR THE POLYMER, AND ORGANIC THIN FILM DEVICE AND ORGANIC THIN FILM TRANSISTOR EACH COMPRISING THE ORGANIC THIN FILM | Osaka University (JP) | 2010-11-17 | — | — | EP | disclosed |
| EP-2061755-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
| WO-2008109840-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-12 | — | — | WO | disclosed |
| EP-0889049-B1 | Novel diarsine compounds | HOFFMANN LA ROCHE (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6037479-A | USEFUL IN ENANTIOSELECTIVE REACTIONS AND WHICH GIVE RISE TO IMPROVED OPTICAL YIELDS | HOFFMAN-LA ROCHE INC. (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0647648-B1 | Optically active phosphorus compounds | HOFFMANN LA ROCHE (CH) | 1999-03-10 | — | — | EP | disclosed |
| EP-0889049-A1 | Novel diarsine compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1999-01-07 | — | — | EP | disclosed |
| US-5516944-A | ENANTIOMORPHS WITH PHOSPHINE GROUPS FOR FORMING METAL COMPLEXES | HOFFMANN-LA ROCHE INC. (US) | 1996-05-14 | — | — | US | disclosed |
| US-5514805-A | ASSYMETRIC HYDROGENATION OF A PYRIDINECARBONYL COMPOUND, RHODIUM PHOSPHINE CATALYST | HOFFMANN-LA ROCHE INC. (US) | 1996-05-07 | — | — | US | disclosed |
| US-5508438-A | Phosphorus compounds | HOFFMANN-LA ROCHE INC. (US) | 1996-04-16 | — | — | US | disclosed |
| EP-0647648-A1 | Optically active phosphorus compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1995-04-12 | — | — | EP | disclosed |
| US-5302738-A | Chiral phosphines | HOFFMANN-LA ROCHE INC. (US) | 1994-04-12 | — | — | US | disclosed |
| US-5274125-A | Chirale phosphines | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | TFRC, SLC40A1, FECH | CYP2A6 763/4885CYP1A2 313/4885TSHR 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.